Subjective cognitive decline (SCD) refers to the self-perception of cognitive decline among cognitively normal elderly individuals. SCD related worry confers a higher risk of developing cognitive decline. However, the clinical characteristics of SCD patients with worry are not clear.
Objective:
To explore the clinical characteristics of SCD patients with worry.
Methods:
A cross-sectional study was carried out, with 270 consecutive participants of the Sino Longitudinal Study on Cognitive Decline (SILCODE) study. Participants were classified as normal controls (n = 36), SCD patients without worry (n = 91), or SCD patients with worry (n = 143) and were comprehensively compared on 1) their self-perception of cognitive decline, 2) multiple cognitive domains, 3) neuropsychiatric symptoms, and 4) sleep status.
Results:
SCD patients with worry had significantly more self-perception of cognitive decline (p < 0.001); increased depression (p < 0.001) and anxiety (p < 0.001); decreased sleep quality (p < 0.001), sleep latency (p < 0.05), sleep time (p < 0.01), and sleep efficiency (p < 0.05); more sleep disorders (p < 0.05) and daytime dysfunction (p < 0.05); and a higher global score on the Pittsburgh Sleep Quality Index (p < 0.001) than normal controls. Although there was a significant increase only in self-perception of cognitive decline (p < 0.001), anxiety (p < 0.001), and Pittsburgh Sleep Quality Index scores (p < 0.05), the severity of the increase in those without worry was between that in SCD patients with worry and normal controls.
Conclusion:
Our findings show that participants who had SCD with worry showed distinct clinical characteristics compared with normal controls and SCD patients without worry, which could be useful for understanding the higher risk in SCD patients with worry of subsequently developing Alzheimer’s disease.
RabinLA, SmartCM, AmariglioRE (2017) Subjective cognitive decline in preclinical Alzheimer’s disease. Annu Rev Clin Psychol13, 369–396.
13.
JessenF, AmariglioRE, van BoxtelM, BretelerM, CeccaldiM, ChetelatG, DuboisB, DufouilC, EllisKA, van der FlierWM, GlodzikL, van HartenAC, de LeonMJ, MchughP, MielkeMM, MolinuevoJL, MosconiL, OsorioRS, PerrotinA, PetersenRC, RabinLA, RamiL, ReisbergB, RentzDM, SachdevPS, de la SayetteV, SaykinAJ, ScheltensP, ShulmanMB, SlavinMJ, SperlingRA, StewartR, UspenskayaO, VellasB, VisserPJ, WagnerM (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement10, 844–852.
14.
van HartenAC, MielkeMM, Swenson-DravisDM, HagenCE, EdwardsKK, RobertsRO, GedaYE, KnopmanDS, PetersenRC (2018) Subjective cognitive decline and risk of MCI. Neurology91, e300–e312.
HuX, TeunissenCE, SpottkeA, HenekaMT, DüzelE, PetersO, LiS, PrillerJ, BuergerK, TeipelS, LaskeC, VerfaillieSCJ, BarkhofF, Coll-PadrósN, RamiL, MolinuevoJL, van der FlierWM, JessenF (2019) Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer’s disease—Data from three memory clinic studies. Alzheimers Dement15, 185–193.
17.
BuckleyRF, HanseeuwB, SchultzAP, VanniniP, AghjayanSL, ProperziMJ, JacksonJD, MorminoEC, RentzDM, SperlingRA, JohnsonKA, AmariglioRE (2017) Region-specific association of subjective cognitive decline with tauopathy independent of global β-amyloid burden. JAMA Neurol74, 1455.
18.
SunY, YangFC, LinCP, HanY (2015) Biochemical and neuroimaging studies in subjective cognitive decline: Progress and perspectives. CNS Neurosci Ther21, 768–775.
19.
JessenF, Rodriguez NéeThen FS (2018) Not all, but specific types of cognitive complaints predict decline to MCI. Neurology91, 153–154.
20.
MolinuevoJL, RabinLA, AmariglioR, BuckleyR, DuboisB, EllisKA, EwersM, HampelH, KlöppelS, RamiL, ReisbergB, SaykinAJ, SikkesS, SmartCM, SnitzBE, SperlingR, van der FlierWM, WagnerM, JessenF (2017) Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement13, 296–311.
21.
JessenF, WieseB, BachmannC, Eifflaender-GorferS, HallerF, KolschH, LuckT, MoschE, van den BusscheH, WagnerM, WollnyA, ZimmermannT, PentzekM, Riedel-HellerSG, RombergH P, WeyererS, KaduszkiewiczH, MaierW, BickelH (2010) Prediction of dementia by subjective memory impairment: Effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry67, 414–422.
22.
JessenF, WolfsgruberS, WieseB, BickelH, MöschE, KaduszkiewiczH, PentzekM, Riedel-HellerSG, LuckT, FuchsA, WeyererS, WerleJ, van den BusscheH, SchererM, MaierW, WagnerM (2014) AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimers Dement10, 76–83.
MckhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
25.
GiffordKA, LiuD, RomanoRR, JonesRN, JeffersonAL (2015) Development of a subjective cognitive decline questionnaire using item response theory: A pilot study. Alzheimers Dement (Amst)1, 429–439.
26.
HamiltonM (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23, 56–62.
27.
HamiltonM (1959) The assessment of anxiety states by rating. Br J Med Psychol32, 50–55.
28.
GuoQ-H, SunY-M, Yu P-M HongZ, LvC-Z (2007) Norm of Auditory Verbal Learning Test in the normal aged in China community. Chin J Clin Psychol15, 132–134.
29.
ZhaoQ-H, GuoQ-H, LiF, ZhouY, WangB, HongZ (2013) The Shape Trail Test: Application of a new variant of the Trail making test. PLoS One8, e57333.
30.
ZhaoQ-H, GuoQ-H, HongZ (2013) Clustering and switching during a semantic verbal fluency test contribute to differential diagnosis of cognitive impairment. Neurosci Bull29, 75–82.
31.
KaplanE, GoodglassH, WeintraubS (1983) The Boston naming test. Lea & Febiger, Philadelphia.
32.
[32] GuoQ-H, ZhouB, ZhaoQ-H, WangB, HongZ (2012) Memory and Executive Screening (MES): A brief cognitive test for detecting mild cognitive impairment. BMC Neurol12, 119.
33.
ChenK-L, XuY, ChuA-Q, DingD, LiangX-N, NasreddineZS, DongQ, HongZ, ZhaoQ-H, GuoQ-H (2016) Validation of the Chinese version of Montreal Cognitive Assessment Basic for screening mild cognitive impairment. J Am Geriatr Soc64, e285–e290.
34.
BuysseDJ, ReynoldsCR, MonkTH, BermanSR, KupferDJ (1989) The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res28, 193–213.
35.
Stiasny-KolsterK, MayerG, SchäferS, MöllerJC, Heinzel-GutenbrunnerM, OertelWH (2007) The REM sleep behavior disorder screening questionnaire-A new diagnostic instrument. Mov Disord22, 2386–2393.
36.
JohnsMW (1991) A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep14, 540–545.
37.
JessenF, SpottkeA, BoeckerH, BrosseronF, BuergerK, CatakC, FliessbachK, FrankeC, FuentesM, HenekaMT, JanowitzD, KilimannI, LaskeC, MenneF, NestorP, PetersO, PrillerJ, ProssV, RamirezA, SchneiderA, SpeckO, SpruthEJ, TeipelS, VukovichR, WesterteicherC, WiltfangJ, WolfsgruberS, WagnerM, DüzelE (2018) Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE). Alzheimers Res Ther10, 15.
38.
ValechN, MollicaMA, OlivesJ, TortA, ForteaJ, LleoA, BelénS, MolinuevoJL, RamiL (2015) Informants’ perception of subjective cognitive decline helps to discriminate preclinical Alzheimer’s disease from normal aging. J Alzheimers Dis48, S87–S98.
39.
ValechN, Tort-MerinoA, Coll-PadrósN, OlivesJ, LeónM, RamiL, MolinuevoJL (2017) Executive and language subjective cognitive decline complaints discriminate preclinical Alzheimer’s disease from normal aging. J Alzheimers Dis61, 689–703.
40.
HaoL-X, WangX-N, ZhangL, XingY, GuoQ-H, HuX-C, MuB, ChenY-L, ChenG-Q, CaoJ, ZhiX-D, LiuJ-J, LiX-Y, YangL, LiJ-C, DuW-Y, SunY, WangT, LiuZ, LiuZ, ZhaoX-X, LiH-Y, YuY, WangX, JiaJ-G, HanY (2017) Prevalence, risk factors, and complaints screening tool exploration of subjective cognitive decline in a large cohort of the Chinese population. J Alzheimers Dis60, 371–388.
41.
ZhaoQ-F, TanL, WangH-F, JiangT, TanM-S, TanL, XuW, LiJ-Q, WangJ, LaiT-J, YuJ-T (2016) The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: Systematic review and meta-analysis. J Affect Disord190, 264–271.
42.
GedaYE, SchneiderLS, GitlinLN, MillerDS, SmithGS, BellJ, EvansJ, LeeM, PorsteinssonA, LanctôtKL, RosenbergPB, SultzerDL, FrancisPT, BrodatyH, PadalaPP, OnyikeCU, OrtizLA, Ancoli-IsraelS, BliwiseDL, MartinJL, VitielloMV, YaffeK, ZeePC, HerrmannN, SweetRA, BallardC, KhinNA, AlfaroC, MurrayPS, SchultzS, LyketsosCG (2013) Neuropsychiatric symptoms in Alzheimer’s disease: Past progress and anticipation of the future. Alzheimers Dement9, 602–608.
43.
ByersA L, YaffeK (2011) Depression and risk of developing dementia. Nat Rev Neurol7, 323–331.
44.
GedaYE, KnopmanDS, MrazekDA, JichaGA, SmithGE, NegashS, BoeveBF, IvnikRJ, PetersenRC, PankratzVS, RoccaWA (2006) Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: A prospective cohort study. Arch Neurol63, 435–440.
45.
GedaYE, RobertsRO, MielkeMM, KnopmanDS, ChristiansonTJH, PankratzVS, BoeveBF, SochorO, TangalosEG, PetersenRC, RoccaWA (2014) Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: A population-based study. Am J Psychiatry171, 572–581.
46.
SteenlandK, KarnesC, SealsR, CarnevaleC, HermidaA, LeveyA (2012) Late-life depression as a risk factor for mild cognitive impairment or Alzheimer’s disease in 30 US Alzheimer’s Disease Centers. J Alzheimers Dis31, 265–275.
47.
DonovanNJ, AmariglioRE, ZollerAS, RudelRK, Gomez-IslaT, BlackerD, HymanBT, LocascioJJ, JohnsonKA, SperlingRA, MarshallGA, RentzDM (2014) Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry22, 1642–1651.
48.
Krell-RoeschJ, LoweVJ, NeureiterJ, PinkA, RobertsRO, MielkeMM, VemuriP, StokinGB, ChristiansonTJ, JackCR, KnopmanDS, BoeveBF, KremersWK, PetersenRC, GedaYE (2018) Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: The Mayo Clinic Study of Aging. Int Psychogeriatr30, 245–251.
49.
PomaraN1, BrunoD, SarrealAS, HernandoRT, NierenbergJ, PetkovaE, SidtisJJ, WisniewskiTM, MehtaPD, PraticoD, ZetterbergH, BlennowK (2012) Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. J Psychiatry169, 523–530.
50.
DonovanNJ, LocascioJJ, MarshallGA, GatchelJ, HanseeuwBJ, RentzDM, JohnsonKA, SperlingRA (2018) Longitudinal association of amyloid beta and anxious-depressive symptoms in cognitively normal older adults. Am J Psychiatry175, 530–537.
51.
HarringtonKD, GouldE, LimYY, AmesD, PietrzakRH, RembachA, Rainey-SmithS, MartinsRN, SalvadoO, VillemagneVL, RoweCC, MastersCL, MaruffP; AIBL Research Group (2017) Amyloid burden and incident depressive symptoms in cognitively normal older adults. Int J Geriatr Psychiatry32, 455–463.
52.
ShiL, ChenSJ, MaMY, BaoYP, HanY, WangYM, ShiJ, VitielloMV, LuL (2018) Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. Sleep Med Rev40, 4–16.
53.
Shokri-KojoriE, WangG, WiersCE, DemiralSB, GuoM, KimSW, LindgrenE, RamirezV, ZehraA, FreemanC, MillerG, ManzaP, SrivastavaT, De SantiS, TomasiD, BenvenisteH, VolkowND (2018) β-Amyloid accumulation in the human brain after one night of sleep deprivation. Proc Natl Acad Sci U S A115, 4483–4488.
54.
LuceyBP, HicksTJ, MclelandJS, ToedebuschCD, BoydJ, ElbertDL, PattersonBW, BatyJ, MorrisJC, OvodV, MawuenyegaKG, BatemanRJ (2018) Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics. Ann Neurol83, 197–204.
55.
HolthJK, FritschiSK, WangC, PedersenNP, CirritoJR, MahanTE, FinnMB, ManisM, GeerlingJC, FullerPM, LuceyBP, HoltzmanDM (2019) The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science363, 880–884.
56.
NobleW, Spires-JonesTL (2019) Sleep well to slow Alzheimer’s progression?Science363, 813–814.
BonanniE, MaestriM, TognoniG, FabbriniM, NucciaroneB, MancaML, GoriS, IudiceA, MurriL (2005) Daytime sleepiness in mild and moderate Alzheimer’s disease and its relationship with cognitive impairment. J Sleep Res14, 311–317.
65.
KielbS, RogalskiE, WeintraubS, RademakerA (2017) Objective features of subjective cognitive decline in a United States national database. Alzheimers Dement13, 1337–1344.
66.
HsuY, HuangC, TuM, HuaM (2015) Prospective memory in subjective cognitive decline: A preliminary study on the role of early cognitive marker in dementia. Alzheimer Dis Assoc Disord29, 229–235.
